Gil Blum
Stock Analyst at Needham
(4.13)
# 661
Out of 5,182 analysts
401
Total ratings
42.34%
Success rate
17.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gil Blum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARTV Artiva Biotherapeutics | Reiterates: Buy | $18 | $12.39 | +45.28% | 9 | May 4, 2026 | |
| CELC Celcuity | Maintains: Buy | $122 → $157 | $139.44 | +12.59% | 25 | May 4, 2026 | |
| NRIX Nurix Therapeutics | Reiterates: Buy | $26 | $16.88 | +54.03% | 31 | Apr 23, 2026 | |
| LYEL Lyell Immunopharma | Initiates: Buy | $44 | $20.85 | +111.03% | 1 | Apr 10, 2026 | |
| AUTL Autolus Therapeutics | Reiterates: Buy | $10 | $1.70 | +488.24% | 36 | Apr 9, 2026 | |
| ABSI Absci | Reiterates: Buy | $7 | $5.95 | +17.65% | 10 | Mar 30, 2026 | |
| NKTX Nkarta | Maintains: Buy | $10 → $11 | $3.32 | +231.33% | 19 | Mar 26, 2026 | |
| SRPT Sarepta Therapeutics | Reiterates: Underperform | n/a | $23.03 | - | 39 | Mar 26, 2026 | |
| SLDB Solid Biosciences | Reiterates: Buy | $19 | $7.20 | +163.89% | 4 | Mar 20, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $10 → $12 | $6.98 | +71.92% | 33 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $8.34 | +403.60% | 17 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $75 | $30.73 | +144.06% | 15 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $3.43 | +133.24% | 26 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $55.08 | +48.87% | 28 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $0.24 | +1,164.76% | 21 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $6 | $1.25 | +380.00% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | n/a | $3.86 | - | 22 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $6.68 | - | 16 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $1.58 | +343.04% | 23 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $10.72 | +347.76% | 9 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $2.29 | - | 9 | Oct 27, 2025 |
Artiva Biotherapeutics
May 4, 2026
Reiterates: Buy
Price Target: $18
Current: $12.39
Upside: +45.28%
Celcuity
May 4, 2026
Maintains: Buy
Price Target: $122 → $157
Current: $139.44
Upside: +12.59%
Nurix Therapeutics
Apr 23, 2026
Reiterates: Buy
Price Target: $26
Current: $16.88
Upside: +54.03%
Lyell Immunopharma
Apr 10, 2026
Initiates: Buy
Price Target: $44
Current: $20.85
Upside: +111.03%
Autolus Therapeutics
Apr 9, 2026
Reiterates: Buy
Price Target: $10
Current: $1.70
Upside: +488.24%
Absci
Mar 30, 2026
Reiterates: Buy
Price Target: $7
Current: $5.95
Upside: +17.65%
Nkarta
Mar 26, 2026
Maintains: Buy
Price Target: $10 → $11
Current: $3.32
Upside: +231.33%
Sarepta Therapeutics
Mar 26, 2026
Reiterates: Underperform
Price Target: n/a
Current: $23.03
Upside: -
Solid Biosciences
Mar 20, 2026
Reiterates: Buy
Price Target: $19
Current: $7.20
Upside: +163.89%
Taysha Gene Therapies
Mar 19, 2026
Maintains: Buy
Price Target: $10 → $12
Current: $6.98
Upside: +71.92%
Mar 9, 2026
Reiterates: Buy
Price Target: $42
Current: $8.34
Upside: +403.60%
Feb 26, 2026
Maintains: Buy
Price Target: $71 → $75
Current: $30.73
Upside: +144.06%
Feb 26, 2026
Reiterates: Buy
Price Target: $8
Current: $3.43
Upside: +133.24%
Feb 13, 2026
Maintains: Buy
Price Target: $80 → $82
Current: $55.08
Upside: +48.87%
Jan 13, 2026
Maintains: Buy
Price Target: $5 → $3
Current: $0.24
Upside: +1,164.76%
Nov 4, 2025
Maintains: Buy
Price Target: $9 → $6
Current: $1.25
Upside: +380.00%
Jul 24, 2025
Maintains: Hold
Price Target: n/a
Current: $3.86
Upside: -
Mar 27, 2025
Reiterates: Hold
Price Target: n/a
Current: $6.68
Upside: -
Jan 13, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $1.58
Upside: +343.04%
Aug 2, 2024
Reiterates: Buy
Price Target: $48
Current: $10.72
Upside: +347.76%
Oct 27, 2025
Reiterates: Hold
Price Target: n/a
Current: $2.29
Upside: -